To overcome this, a wide range of CARs against multiple antigens that are expressed by CRC (GUCY2C (80), EpCAM (81), NKG2D (82), Her2 (83), MUC (84), etc.)are being evaluated using in vitro and pre-clinical animal models. Here, EPCAM is linked to colorectal carcinoma.